Skip to main content

SGNLVA-005 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

NCT04032704

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

Sponsor

Seattle Genetics

We are doing this study to find out if ladiratuzumab vedotin works for solid tumor cancers and what kind of side effects it causes.

This study is currently enrolling.